Shots:
The Healthcare IPOs in 2025 underscore sustained investor confidence across biotech, medtech, digital health, and AI-enabled healthcare companies, signaling robust capital deployment into next-generation therapies, advanced diagnostics, and evolving healthcare delivery models worldwide.
IPO activity was dominated by high-value raises, with Medline Industries ($7.2B) leading by a wide margin, followed by Caris Life Sciences…
TOP 20
Shots:
From AI-powered discovery to next-generation biologics and gene editing, 2025 was a blockbuster year for life sciences dealmaking. Pharma and biotech companies signed multibillion-dollar partnerships and acquisitions to accelerate innovation across oncology, cardiometabolic diseases, neurology, and rare disorders.
Platform technologies dominated the deal landscape, with big pharma securing access to cutting-edge modalities from bispecific…
Shots:
Women leaders are reshaping the healthcare industry, bringing visionary leadership, scientific expertise, and strategic insight to traditionally male-dominated spaces
From biotech innovation to global pharmaceutical enterprises, these trailblazers are driving transformative solutions, advancing patient care, and championing inclusive workplace cultures
PharmaShots spotlights 20 extraordinary women leaders in healthcare, celebrating their achievements, impact, and inspiring journeys that…
Shots:
The Top 20 Radiopharma Companies of 2026, ranked by market capitalization, represent a powerful mix of global pharmaceutical leaders and agile innovators transforming radioligand therapies, alpha-emitters, and copper-based theranostics into pillars of modern oncology. What was once niche science is now redefining precision cancer care.
Flagship therapies such as Lutathera, Pluvicto, Pylarify, Illuccix/Gozellix, Xofigo,…
Top 20 Emerging Animal Health Companies Worldwide in 2026
Shots:
Emerging companies in the animal health sector are gaining ground in livestock, poultry, equine, and companion animal markets. Small and mid-sized innovators offer affordable care models, targeted biologics, and sustainable solutions for global needs
These firms bolster their positions via portfolio growth, partnerships, acquisitions, and…
Shots:
2025 pharma M&A was defined by fewer but more transformational deals, with companies prioritizing commercial-stage assets, late-stage pipelines, and platform technologies capable of reshaping long-term growth and strengthening core therapeutic franchises
The year’s momentum was led by three standout transactions, J&J’s $14.6B acquisition of Intra-Cellular Therapies, Novartis’ $12B deal for Avidity Biosciences, and Merck’s…
Shots:
AI is revolutionizing healthcare, reshaping drug discovery, protein design, and precision therapeutics. Companies are now tackling previously “undruggable” targets and moving treatments through development pipelines faster than ever
The AI in the healthcare market is exploding. From a valuation of $26.57B in 2024, it is projected to reach $505.59B by 2033, growing at a CAGR of 38.8%. This rapid…
Shots:
Animal health companies remain fundamental to global veterinary care and modern food production, driving innovation across pharmaceuticals, vaccines, diagnostics, and digital technologies that support the health of both companion animals and livestock
The sector continues to deliver robust, steady growth, fueled by rising pet ownership, increasing demand for safe and sustainable protein, and rapid…
Shots:
CDMOs have become central to the modern biopharmaceutical ecosystem, helping companies accelerate development timelines, navigate rising technical complexity, and bring innovative therapies to market with greater efficiency
The global CDMO market continues to post strong double-digit growth and is projected to reach nearly $255B by 2025. This momentum is driven by increased outsourcing, the…
Shots:
In 2025, the global Prescription Drugs market is projected to generate an impressive $1.13T, with steady annual growth of 3.94% expected through 2030, ultimately reaching $1.37T. Leading the pack is Keytruda, securing the first position with $29.48B, closely followed by Ozempic at $28.18B, and Eliquis, which recorded $20.69B in global sales. Fourth position is…

